Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
about
PLK-1 Targeted Inhibitors and Their Potential against TumorigenesisA high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1Polo-like kinase and its inhibitors: Ready for the match to start?Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translationStructure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoniA randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative netwA phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cellsGSK-3 modulates cellular responses to a broad spectrum of kinase inhibitorsTherapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibitionTargeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer TreatmentFOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas.Recent Advances and New Strategies in Targeting Plk1 for Anticancer TherapyEpithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisationThe PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutationsHuman ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.The centrosome as potential target for cancer therapy and prevention.Mitosis-targeted anti-cancer therapies: where they stand.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Mitosis as an anti-cancer drug target.Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy.Interphase microtubules: chief casualties in the war on cancer?Current assessment of polo-like kinases as anti-tumor drug targets.Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development.Targeted therapy of acute myeloid leukemia.Targeting polo-like kinase 1 in acute myeloid leukemia.The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent.Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells.Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
P2860
Q26777811-9855DFC1-AAD1-417B-AC98-879456E55CE5Q27304385-36C56CB4-4629-4EAB-B9B8-F9B304706BFDQ28087433-CD1D4BCD-9F96-41AE-B3AC-C2BCF48018B5Q28478937-D7824861-AC77-4EC9-94C9-3DD14AB72A0EQ28552326-7FE2DCC5-C7A3-4357-85FC-714215ED52F9Q33401811-B5D12FE7-2905-40DC-B5EB-5BEA607E62F3Q33414793-CE71F40A-EF64-4379-9EC7-2D4E272D4128Q33428061-2C3BF6B1-CCC2-4FF1-98BA-B1168C2D29D9Q33873351-9E80DAB2-2121-4A8C-8D74-C81290CE625EQ34184864-9E76AAB8-877B-4EA9-BEB5-1462477B4C8BQ34735363-4F419376-83D1-4C12-893A-C0E7A15EB50FQ35092019-FE042236-5662-4B1A-A975-04C488E9758AQ35801683-8A4B0178-8A92-4E7E-B2D5-16715F240EF1Q35843942-71D38C40-38D9-4AFD-BAF2-0471E10B0348Q36386336-6658956C-3153-4BEB-B736-660CE258D51DQ36759439-98E07834-BB53-4E00-8C9D-4451012E2BC6Q37126130-B51A82C8-5EB8-4925-B78B-9A52CB93C13DQ37199459-DC5ADF3A-E6E2-4B4C-82EE-7EFE5DD14229Q37218015-5F993037-6CE4-4C7C-8652-96D54EDD1F22Q37701672-C24B9670-E0D4-4B51-8D6A-C03E36D5E266Q37909373-4B6F366E-E09F-4255-BA09-E3D2C4A016E8Q37994256-07C114D2-FB91-4D8D-9891-93F8EF3D959AQ37998019-C6942D0C-83D3-4027-A392-3DB7E2200074Q38051759-E632EC97-D83D-424A-ABAB-74E69F7DC156Q38053055-90768013-7DD1-40BB-91D6-35545C75D477Q38099046-8151B06F-FD7B-4A02-BEFD-5396724ADB29Q38115166-0699F9B9-3B6B-4F1C-81CD-2CF48DCF34B0Q38129174-54CAC83F-4B86-4E40-AAE5-0FA8837CAAFDQ38160670-E4B905AF-7BD1-4ACD-AEC6-4DC7967B321BQ38211244-E6804005-50A3-4DD1-AE00-D29F0845B359Q38221687-B0AC08B9-4AEF-4377-9B36-BDD7E15A6173Q38333251-B4A66212-8472-47BC-88F1-4A4ADBB7D296Q38398864-579B191C-0DC2-4392-9614-C7542291A60DQ38671515-ABB085CD-CC14-4F09-9B73-6DCA39BFE0B8Q38695896-EFBC8C5D-6EAF-4F18-ABA3-AE39E7761D2CQ38742560-6F13B75C-9028-46C4-A219-2266A8D43ACBQ38793115-FFE9ABBA-4014-46CD-B568-BBE322453BFBQ38872725-F36CEEDA-466C-41CC-836E-4634B6519813Q38982783-63D7F755-E85F-40CF-ACD1-D95190B06621Q38989539-15780BD9-1BE5-41C3-8628-BC589667B3C1
P2860
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase I study of GSK461364, a ...... h advanced solid malignancies.
@ast
Phase I study of GSK461364, a ...... h advanced solid malignancies.
@en
type
label
Phase I study of GSK461364, a ...... h advanced solid malignancies.
@ast
Phase I study of GSK461364, a ...... h advanced solid malignancies.
@en
prefLabel
Phase I study of GSK461364, a ...... h advanced solid malignancies.
@ast
Phase I study of GSK461364, a ...... h advanced solid malignancies.
@en
P2093
P1476
Phase I study of GSK461364, a ...... h advanced solid malignancies.
@en
P2093
Alicia J Allred
Andre T Brunetto
Anne B Taegtmeyer
David Olmos
Deborah A Smith
Douglas Barker
Hanine Medani
Johann S de Bono
Mohammed M Dar
Richard Wilson
P304
P356
10.1158/1078-0432.CCR-10-2946
P407
P577
2011-04-01T00:00:00Z